AU679462B2 - Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation - Google Patents

Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation

Info

Publication number
AU679462B2
AU679462B2 AU50923/93A AU5092393A AU679462B2 AU 679462 B2 AU679462 B2 AU 679462B2 AU 50923/93 A AU50923/93 A AU 50923/93A AU 5092393 A AU5092393 A AU 5092393A AU 679462 B2 AU679462 B2 AU 679462B2
Authority
AU
Australia
Prior art keywords
carbon atoms
hydrogen
carvedilol
lower alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50923/93A
Other languages
English (en)
Other versions
AU5092393A (en
Inventor
Eliot H. Ohlstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM Corp NO 1 LP
Original Assignee
Boehringer Mannheim Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/026,892 external-priority patent/US5308862A/en
Application filed by Boehringer Mannheim Pharmaceuticals Corp filed Critical Boehringer Mannheim Pharmaceuticals Corp
Publication of AU5092393A publication Critical patent/AU5092393A/en
Application granted granted Critical
Publication of AU679462B2 publication Critical patent/AU679462B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU50923/93A 1993-03-05 1993-08-27 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation Ceased AU679462B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US026892 1993-03-05
USUS93/02062 1993-03-05
PCT/US1993/002062 WO1994020096A1 (en) 1993-03-05 1993-03-05 Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US08/026,892 US5308862A (en) 1993-03-05 1993-03-05 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
PCT/US1993/008019 WO1994020097A1 (en) 1993-03-05 1993-08-27 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation

Publications (2)

Publication Number Publication Date
AU5092393A AU5092393A (en) 1994-09-26
AU679462B2 true AU679462B2 (en) 1997-07-03

Family

ID=26701782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50923/93A Ceased AU679462B2 (en) 1993-03-05 1993-08-27 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation

Country Status (7)

Country Link
EP (1) EP0746315A4 (no)
JP (1) JPH08508013A (no)
AU (1) AU679462B2 (no)
NO (1) NO307865B1 (no)
RU (1) RU2147433C1 (no)
UA (1) UA41915C2 (no)
WO (2) WO1994020096A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US4970227A (en) * 1984-11-20 1990-11-13 Burroughs Wellcome Co. Carbazole derivatives

Also Published As

Publication number Publication date
WO1994020096A1 (en) 1994-09-15
EP0746315A4 (en) 1999-01-07
RU2147433C1 (ru) 2000-04-20
EP0746315A1 (en) 1996-12-11
NO953480D0 (no) 1995-09-04
UA41915C2 (uk) 2001-10-15
WO1994020097A1 (en) 1994-09-15
AU5092393A (en) 1994-09-26
NO307865B1 (no) 2000-06-13
NO953480L (no) 1995-11-03
JPH08508013A (ja) 1996-08-27

Similar Documents

Publication Publication Date Title
US5308862A (en) Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
Ohlstein et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.
EP0808162B1 (en) Use of carbazole compounds for the manufacture of a medicament for the treatment of congestive heart failure
KR101519028B1 (ko) 항혈관형성제 및 사용방법
US20050131049A1 (en) Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
US6096777A (en) Method for inhibiting the expression of Fas
KR20050106038A (ko) 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제
US20030158247A1 (en) Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
AU735980B2 (en) A method of treating liver disease and like indications with vasodilating agents
JPH0390027A (ja) 排尿障害治療剤
JP4836388B2 (ja) ｅＮＯＳ発現に起因する疾患の予防または治療薬
AU679462B2 (en) Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
RU2339381C2 (ru) Ингибитор гиперплазии интимы сосудов
US6174917B1 (en) Method of treating liver disease and like indications with vasodilating agents
JP2006089455A (ja) 動脈瘤予防および／または治療剤
CA2170289C (en) A method of treating liver disease and like indications with vasodilating agents
US20060009475A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
AU778129B2 (en) A method of treating liver disease and like indications with vasodilating agents
JP2004250442A (ja) エンドセリン血中濃度低下剤
JPH0827029A (ja) ５ｈｔ１ 作動薬の新規医薬用途
AU9142098A (en) A method of treating liver disease and like indications with vasodilating agents